Insulet gains fresh analyst support, shares trade near 52-week low on NASDAQ

Deutsche Bank starts coverage of Insulet with a Buy rating and a $190 price target, highlighting growth in diabetes devices while the shares remain close to their 52-week low.

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 19:15.

Insulet (US45784P1012) draws fresh attention on NASDAQ after Deutsche Bank initiated coverage with a Buy rating and a $190 price target, according to a Tuesday note. The shares trade around $139, close to a 52-week low, per Investing.com data. Deutsche Bank initiation report on Insulet

What Deutsche Bank highlights

Deutsche Bank bases its $190 price target on roughly 13 times Insulet’s projected 2027 enterprise value to EBITDA, positioning the stock as a growth play in diabetes technology. Details on valuation assumptions from Investing.com The bank points to Insulet’s 32 percent revenue growth over the last twelve months as a key pillar of its positive stance.

Despite this operational expansion, Insulet shares have declined about 51 percent over the past six months, leaving the valuation below many peers in the diabetes-device space. Performance data cited in the analyst report Insulet is grouped with DexCom and Tandem Diabetes Care in Deutsche Bank’s sector review, underscoring the competitive dynamics in insulin delivery and glucose monitoring. Seeking Alpha summary of Deutsche Bank’s MedTech coverage

Consensus views on the Insulet stock

The Deutsche Bank call adds to an already active analyst landscape around Insulet. Benchmark has reiterated a Buy rating with a $250 price target, reflecting confidence in long-term growth in insulin-delivery systems. Investing.com summary of Benchmark’s stance Truist Securities, meanwhile, maintains a Buy but has trimmed its target to $219, citing valuation considerations after the share-price drawdown.

Credit quality indicators have become more mixed. Moody’s has revised Insulet’s outlook from stable to negative in response to product recall issues earlier in the year, estimating an $80 million cost that remains manageable against the company’s revenue scale. Moody’s outlook change as reported by Investing.com This combination of cautious credit commentary and supportive equity research keeps Insulet firmly in focus for US healthcare investors.

The business behind the Insulet stock

Insulet’s core business is tubeless insulin delivery for people living with diabetes. The company’s flagship product family, marketed under the Omnipod brand, offers wearable insulin pumps designed to replace multiple daily injections and integrate with automated insulin delivery algorithms. Insulet product and company overview Insulet also develops subcutaneous drug delivery systems for non-insulin therapies, expanding its addressable market beyond diabetes care.

Where the Insulet shares trade today

Insulet shares (US45784P1012) trade on NASDAQ at around $138.97 as of 2026-06-23, 18:10 Eastern Time, according to recent quote data, leaving the stock close to its 52-week low near $138.79. Latest price information for Insulet

Key data on the Insulet shares

• Company: Insulet Corporation
• ISIN: US45784P1012
• WKN: A0JM2H
• Ticker: PODD
• Trading venue: NASDAQ
• Price (as of 2026-06-23, 18:10): 138.97 USD
• Market cap: approximately 9.6 billion USD (as of 2026-06-23)
• Sector / industry: Health Care Equipment & Supplies
• Index membership: S&P 500
• Next earnings date: 2026-08-01 (company guidance and market estimates)

Disclaimer: This article is for informational purposes only and does not contain investment advice, recommendations or price forecasts. All data and assessments are based on sources cited and may change over time.